Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
A small Ottawa study found psilocybin microdoses significantly reduced depression and anxiety in palliative care patients, including those with advanced ALS, with 62% showing over 50% symptom improvement and no serious side effects.
A small Ottawa study found that microdoses of psilocybin significantly reduced depression and anxiety in palliative care patients, including those with advanced ALS.
Of 20 participants, 62% saw over 50% improvement in depression symptoms with no serious side effects.
The treatment offered rapid relief for existential distress, a common but hard-to-treat issue at end-of-life, and helped some patients like ALS patient Andrew Chernysh regain a sense of meaning and hope.
While psilocybin remains illegal in most contexts, researchers say the results suggest it could be a promising, scalable option for managing emotional suffering in dying patients, warranting further study.
Un pequeño estudio de Ottawa encontró que las microdosis de psilocibina redujeron significativamente la depresión y la ansiedad en pacientes en cuidados paliativos, incluidos aquellos con ELA avanzada, con un 62% que mostró una mejoría de los síntomas de más del 50% y sin efectos secundarios graves.